Your browser doesn't support javascript.
loading
Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury.
Jadidi, Khosrow; Panahi, Yunes; Ebrahimi, Ali; Mafi, Mostafa; Nejat, Farhad; Sahebkar, Amirhossein.
Afiliação
  • Jadidi K; Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran ; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Panahi Y; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Ebrahimi A; Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Mafi M; Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Nejat F; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Sahebkar A; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
J Ophthalmic Vis Res ; 9(4): 417-22, 2014.
Article em En | MEDLINE | ID: mdl-25709764
PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. RESULTS: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. CONCLUSION: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Ophthalmic Vis Res Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Ophthalmic Vis Res Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Irã